Metastases of esophageal carcinoma to skeletal muscle: Single center experience

Table 1 Patients with esophageal carcinoma and skeletal muscle metastases in the present series

Patient	Age at diagnosis (yr)	Histology	Stage at diagnosis	Timing	Primary therapy	Metastatic interval (mo)	Symptoms	Diagnosis	Location	Other metastases	Therapy for muscle metastases	Survival from the diagnosis of muscle metastasis (mo)
1	64	Adeno	II	Metachronous	CXRT	32	Mass	PET/CT; biopsy	Quadriceps femoris	B; LN (subs)	CXRT	31
2	76	SCC	III	Metachronous	CXRT	5	None	PET/CT; biopsy	Gluteus minimus; psoas	L; P; A; LN (subs)	CXRT	16
3	57	SCC	IV	Synchronous	None	0	None	PET/CT	Subscapularis	B	CRT; subs XRT	5
4	42	Adeno	IV	Synchronous	CXRT	0	None	PET/CT; biopsy	Iliacus	PR	S	16
5	60	SCC; adeno (pancreas)	IV	Synchronous	None	0	None	PET/CT; autopsy	Multiple	Multiple	None	2

A: Adrenal; Adeno: Adenocarcinoma; B: Bone; CRT: Chemotherapy; CXRT: Chemoradiation; L: Lungs; P: Pleura; PR: Peritoneum; LN: Lymph nodes; S: Surgery; SCC: Squamous cell carcinoma; subs: Subsequently; XRT: Radiotherapy; PET/CT: Positron emission tomography/computed tomography.